Etherstack (ASX:ESK) delivers strong revenue and earnings growth as recurring income builds


Published 22-FEB-2017 13:34 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Etherstack plc (ASX: ESK) has delivered an impressive full-year result for the 12 months to December 31, 2016, having achieved revenue growth of 169% and earnings before interest, tax depreciation and amortisation (EBITDA) of US$836,000, a significant improvement on the previous year’s loss of US$703,000.

From an operational perspective it has been a successful year for the group having been awarded several multi-million dollar projects in North America. Most of these have related to large corporates and utilities that provide the company with exposure to defensive earnings streams.

ESK also broadened its customer base in Australia having received its first order from the Australian Department of Defence

Recurring revenue growing exponentially

The company boasts strong recurring revenue, with royalty income increasing exponentially relative to group revenues on a year on year basis.

Income from support and royalties nearly doubled from US$550,000 in 2015 to US$1.07 million in 2016 and now accounts for approximately 18% of group revenues. Notably, royalty revenue grew by 180% on a year-on-year basis.

This provides earnings visibility and predictability, making growth of royalties and income from ongoing support a key focus for the group. Chief financial officer, David Carter, said he expected robust growth in this area in fiscal 2017, and he will be updating the market on the company’s progress.

Just how much growth remains to be seen and investors considering this stock for their portfolio, should seek professional financial advice.

ESK has finished the year in a sound financial position as it transitioned to a cash flow positive operation. Furthermore, financing costs were reduced through the repayment of convertible notes following a capital raising.

Carter expects this trend to continue in fiscal 2017 due to a substantial reduction in interest costs.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free